Alfonso Berrocal
About
Alfonso Berrocal is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Alfonso Berrocal has authored 30 papers receiving a total of 381 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Alfonso Berrocal's work include Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (8 papers) and Immunotherapy and Immune Responses (6 papers). Alfonso Berrocal is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (8 papers) and Immunotherapy and Immune Responses (6 papers). Alfonso Berrocal collaborates with scholars based in Spain, United States and Australia. Alfonso Berrocal's co-authors include Carmen Balañá, José A. López-Martín, Óscar Gallego, Gaspar Reynés, Blanca Homet, Alise Reicin, María Ochoa de Olza, Amy T. Ko, Alfonso Gúrpide and Thomas Littlejohn and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.
In The Last Decade
Alfonso Berrocal
29 papers receiving 368 citations
Peers
Alfonso Berrocal
Khoon Leong Chuah Singapore
Francesca Consoli Italy
Izumi Mochimatsu Japan
R. Dollner Germany
Josef Kovařík United Kingdom
Deniz Yamaç Türkiye
Mária Gődény Hungary
Patrick Tassone United States
Jeryl Villadolid United States
Zijun Zhen China
Citations per year, relative to Alfonso Berrocal Alfonso Berrocal (= 1×)
peers
Khoon Leong Chuah
Countries citing papers authored by Alfonso Berrocal
Since
Specialization
Citations
This map shows the geographic impact of Alfonso Berrocal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfonso Berrocal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfonso Berrocal more than expected).
Fields of papers citing papers by Alfonso Berrocal
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Alfonso Berrocal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfonso Berrocal. The network helps show where Alfonso Berrocal may publish in the future.
Co-authorship network of co-authors of Alfonso Berrocal
This figure shows the co-authorship network connecting the top 25 collaborators of Alfonso Berrocal. A scholar is included among the top collaborators of Alfonso Berrocal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alfonso Berrocal. Alfonso Berrocal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Weiss, Sarah A., Mario Sznol, Montaser Shaheen, et al.. (2023). A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy. Clinical Cancer Research. 30(1). 74–81.
2.
Berciano‐Guerrero, Miguel‐Ángel, Ainara Soria, Guillermo Crespo, et al.. (2023). 1174P Sex differences in advanced melanoma in Spain: Results from the prospective real-world study GEM 1801. Annals of Oncology. 34. S697–S698.
3.
Márquez‐Rodas, Iván, Miguel‐Ángel Berciano‐Guerrero, Ainara Soria, et al.. (2022). 848P Second-line systemic treatment for patients with advanced melanoma: Results from the prospective real-world study GEM1801. Annals of Oncology. 33. S937–S938.
4.
Márquez‐Rodas, Iván, Ana Arance, Miguel‐Ángel Berciano‐Guerrero, et al.. (2022). 826P Encorafenib and binimetinib followed by radiotherapy for patients with symptomatic BRAF mutated melanoma brain metastases: GEM1802/E-BRAIN clinical trial. Annals of Oncology. 33. S926–S926.
5.
Deva, Sanjeev, Jacek Mackiewicz, Stéphane Dalle, et al.. (2022). Abstract CT557: Phase 1/2 study of quavonlimab (Qmab) + pembrolizumab (pembro) in patients (pts) with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor. Cancer Research. 82(12_Supplement). CT557–CT557.
6.
Ochenduszko, Sebastián, et al.. (2022). Real-world study on characteristics of advanced melanoma patients with sustained complete response (CR) after elective 1st line anti-programmed death-1 (anti-PD1) monotherapy discontinuation.. Journal of Clinical Oncology. 40(16_suppl). e21529–e21529.
7.
Márquez‐Rodas, Iván, Miguel‐Ángel Berciano‐Guerrero, Ainara Soria, et al.. (2021). 1056P Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study. Annals of Oncology. 32. S881–S882.
8.
Salama, April K.S., Jens T. Siveke, Alfonso Berrocal, et al.. (2021). 1014P Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma. Annals of Oncology. 32. S855–S855.
9.
Weiss, Sarah A., Mario Sznol, Montaser Shaheen, et al.. (2021). 389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy. SHILAP Revista de lepidopterología. A422–A422.
10.
Majem, Margarita, Eva Muñoz‐Couselo, Delvys Rodríguez‐Abreu, et al.. (2020). SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). Clinical & Translational Oncology. 22(2). 213–222.
11.
Westhovens, René, Dae‐Hyun Yoo, Piotr Wiland, et al.. (2020). THU0186 CLINICAL EVALUATION OF THE IMMUNOGENICITY TO CT-P13 FOR SUBCUTANEOUS USE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: 1-YEAR CLINICAL RESULTS FROM A MULTICENTER, RANDOMIZED CONTROLLED PIVOTAL TRIAL. Annals of the Rheumatic Diseases. 79. 310–311.
12.
Berrocal, Alfonso, et al.. (2020). Infusion reaction to nivolumab in a metastatic melanoma patient. Safe switch to another anti-programmed death-1: a case report. Melanoma Research. 31(1). 88–91.
13.
Estival, Anna, Carolina Sanz, José Luis Ramírez, et al.. (2019). Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients. Scientific Reports. 9(1). 11125–11125.
14.
Barco, E. del, Ricard Mesı́a, Joaquina Martínez-Galán, et al.. (2016). Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study. Oral Oncology. 62. 54–59.
15.
Sepúlveda-Sánchez, Juan Manuel, Cristóbal Belda-Iniesta, Miguel Gil‐Gil, et al.. (2015). A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. Clinical & Translational Oncology. 17(9). 743–750.
16.
López-Martín, José A., María González Cao, María Sereno, et al.. (2012). Ipilimumab in Older Patients: Spanish Melanoma Multidisciplinary Group (GEM) Experience in the Expanded Access Programme. Annals of Oncology. 23. ix374–ix375.
17.
Berrocal, Alfonso, Pedro Pérez Segura, Carmen Balañá, et al.. (2009). Extended-schedule dose-dense temozolomide in refractory gliomas. Journal of Neuro-Oncology. 96(3). 417–422.
18.
Carles, Joan, Emilio Esteban, José A. Martínez-Climent, et al.. (2007). Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Annals of Oncology. 18(8). 1359–1362.
19.
Boice, Judith A., Thomas Littlejohn, Pedro C. Miranda, et al.. (2007). A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis and Cartilage. 15(12). 1348–1356.
20.
Fonseca, Emilio, Juan J. Grau, Javier Sastre, et al.. (2005). Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: A randomised phase II study. European Journal of Cancer. 41(9). 1254–1260.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Khoon Leong Chuah Breakdown of academic impact, for papers by Francesca Consoli Breakdown of academic impact, for papers by Izumi Mochimatsu Breakdown of academic impact, for papers by R. Dollner Breakdown of academic impact, for papers by Josef Kovařík Breakdown of academic impact, for papers by Deniz Yamaç Breakdown of academic impact, for papers by Mária Gődény Breakdown of academic impact, for papers by Patrick Tassone Breakdown of academic impact, for papers by Jeryl Villadolid Breakdown of academic impact, for papers by Zijun Zhen